Vanguard Group
ICCC icon

Vanguard Group’s ImmuCell ICCC Stock Holding History

Vanguard Group’s Portfolio ICCC Stock Details ICCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.86M Sell
302,996
-5,706
-2% -$33.6K ﹤0.01% 3579
2025
Q3 		$2M Hold
308,702
– – ﹤0.01% 3585
2025
Q2 		$2.15M Buy
308,702
+83,107
+37% +$485K ﹤0.01% 3513
2025
Q1 		$1.08M Hold
225,595
– – ﹤0.01% 3686
2024
Q4 		$1.16M Hold
225,595
– – ﹤0.01% 3713
2024
Q3 		$819K Hold
225,595
– – ﹤0.01% 3829
2024
Q2 		$1.09M Buy
225,595
+9,268
+4% +$44.6K ﹤0.01% 3762
2024
Q1 		$1.15M Buy
216,327
+9,721
+5% +$50.1K ﹤0.01% 3765
2023
Q4 		$1.05M Buy
206,606
+1,509
+0.7% +$7.36K ﹤0.01% 3814
2023
Q3 		$1.1M Sell
205,097
-1,228
-0.6% -$6.23K ﹤0.01% 3800
2023
Q2 		$1.03M Hold
206,325
– – ﹤0.01% 3890
2023
Q1 		$1.05M Hold
206,325
– – ﹤0.01% 3899
2022
Q4 		$1.26M Buy
206,325
+3,596
+2% +$26K ﹤0.01% 3832
2022
Q3 		$1.52M Sell
202,729
-1,000
-0.5% -$8.17K ﹤0.01% 3856
2022
Q2 		$1.77M Sell
203,729
-596
-0.3% -$5.17K ﹤0.01% 3857
2022
Q1 		$1.97M Buy
204,325
+37,081
+22% +$320K ﹤0.01% 3964
2021
Q4 		$1.34M Buy
167,244
+20,008
+14% +$179K ﹤0.01% 4174
2021
Q3 		$1.38M Hold
147,236
– – ﹤0.01% 4169
2021
Q2 		$1.4M Buy
147,236
+12,625
+9% +$123K ﹤0.01% 4073
2021
Q1 		$1.3M Buy
134,611
+41,230
+44% +$387K ﹤0.01% 3955
2020
Q4 		$556K Hold
93,381
– – ﹤0.01% 3938
2020
Q3 		$507K Hold
93,381
– – ﹤0.01% 3815
2020
Q2 		$441K Sell
93,381
-1,200
-1% -$5.23K ﹤0.01% 3796
2020
Q1 		$359K Hold
94,581
– – ﹤0.01% 3741
2019
Q4 		$487K Hold
94,581
– – ﹤0.01% 3802
2019
Q3 		$525K Buy
94,581
+627
+0.7% +$3.67K ﹤0.01% 3808
2019
Q2 		$611K Buy
93,954
+15,885
+20% +$101K ﹤0.01% 3793
2019
Q1 		$496K Buy
78,069
+256
+0.3% +$1.83K ﹤0.01% 3772
2018
Q4 		$531K Buy
77,813
+6,344
+9% +$49K ﹤0.01% 3725
2018
Q3 		$595K Buy
71,469
+303
+0.4% +$2.18K ﹤0.01% 3818
2018
Q2 		$485K Buy
71,166
+25,300
+55% +$182K ﹤0.01% 3826
2018
Q1 		$321K Buy
45,866
+13,000
+40% +$95.2K ﹤0.01% 3880
2017
Q4 		$289K Buy
32,866
+300
+0.9% +$2.45K ﹤0.01% 3865
2017
Q3 		$210K Sell
32,566
-1,542
-5% -$10.1K ﹤0.01% 3909
2017
Q2 		$250K Hold
34,108
– – ﹤0.01% 3861
2017
Q1 		$186K Hold
34,108
– – ﹤0.01% 3913
2016
Q4 		$203K Buy
34,108
+12,433
+57% +$75.7K ﹤0.01% 3889
2016
Q3 		$167K Sell
21,675
-1,200
-5% -$8.73K ﹤0.01% 3927
2016
Q2 		$158K Buy
22,875
+500
+2% +$3.38K ﹤0.01% 3977
2016
Q1 		$152K Buy
22,375
+10,400
+87% +$69.3K ﹤0.01% 3989
2015
Q4 		$88K Hold
11,975
– – ﹤0.01% 4091
2015
Q3 		$74K Buy
11,975
+1,900
+19% +$15.5K ﹤0.01% 4118
2015
Q2 		$81K Sell
10,075
-400
-4% -$2.75K ﹤0.01% 4129
2015
Q1 		$70K Hold
10,475
– – ﹤0.01% 4103
2014
Q4 		$51K Hold
10,475
– – ﹤0.01% 4019
2014
Q3 		$52K Buy
+10,475
New +$49K ﹤0.01% 3991

Other funds holding ICCC

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
S
Steadtrust Allen, Texas $198M AUM 99.37% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Vanguard Group's ICCC Position: Q4 2025 in Review

Vanguard Group reduced its ImmuCell (ICCC) stake by 1.8% in Q4 2025, selling an estimated $33.6K and leaving 302,996 shares worth $1.86M. The position accounts for ﹤0.01% of the portfolio, ranked #3579.

Vanguard Group first reported a position in ICCC in Q3 2014 and has held it in 46 quarters since. The position peaked at $2.15M in Q2 2025. 26 funds tracked by Wall St. Rank hold ICCC as of Q4 2025.

  • Vanguard Group held 302,996 shares of ImmuCell worth $1.86M as of Q4 2025.
  • Vanguard Group sold 5,706 ImmuCell shares in Q4 2025, an estimated $33.6K.
  • ImmuCell made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3579 holding.
  • Vanguard Group first reported a position in ImmuCell in Q3 2014 and has held it in 46 quarters since.
  • Vanguard Group's ImmuCell position peaked at $2.15M in Q2 2025.
  • 26 funds tracked by Wall St. Rank held ImmuCell as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.